Floatz logo

Atezolizumab

Bladder Transitional Cell Carcinoma

KaliVir Immunotherapeuticsmonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

36 Active assets in the Bladder Transitional Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Nagoya University
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
Nivolumab
Nagoya University
Phase 3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmActive
BB
Indicative · Phase 2/3
71 / 100
View asset →
Her2-receptor negative breast cancerActive
BB
Indicative · Phase 2
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →